Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Expert Rev Clin Immunol ; 17(5): 539-544, 2021 05.
Article in English | MEDLINE | ID: mdl-33734916

ABSTRACT

Background: Psoriatic arthritis is a chronic inflammatory condition. It impacts patients both physically and psychologically. Fatigue may be an early symptom of PsA, which impairs quality of life.Objectives: To assess serum IL-17, fatigue, quality of life and function impairment in PsA patients and to correlate them with clinical disease activity.Methods: 80 consecutive PsA patients were included. Fatigue assessed by Functional Assessment of Chronic Illness Therapy-Fatigue. Quality of life assessed by Psoriatic Arthritis Quality of Life. Functional capacity assessed by health assessment questionnaire. Disease activity assessed by Disease Activity in Psoriatic Arthritis. Serum IL-17 measured by ELISA.Results: There was significant difference in FACIT-F, PsAQOL, and HAQ (p<0.001) in different disease activity subgroups. There was statistically significant correlation of disease duration with disease activity, fatigue, reduced function capacity, and quality of life impairment (p≤0.05), while no correlation with the patients' age. There was statistically significant correlation between FACIT-F, PsAQOL, HAQ, and DAPSA scores (p<0.001). Serum IL-17 was significantly correlated with clinical parameters of disease activity, fatigue, function, and quality of life impairment (p≤0.05).Conclusion: Fatigue is a common clinical symptom in psoriatic arthritis patients. It is significantly associated with IL17, quality of life, functional impairment and disease activity.


Subject(s)
Arthritis, Psoriatic , Quality of Life , Arthritis, Psoriatic/diagnosis , Fatigue/diagnosis , Humans , Interleukin-17 , Severity of Illness Index , Surveys and Questionnaires
2.
Phys Sportsmed ; 49(4): 480-487, 2021 11.
Article in English | MEDLINE | ID: mdl-33283581

ABSTRACT

Objective: The aim of this work is to compare the clinical, functional, and ultrasonographic outcomes of focused, radial, and combined extracorporeal shock-wave therapy (ESWT) in the treatment of calcific shoulder tendinopathy.Methods: we enrolled 45 patients with calcific shoulder tendinopathy, their ages ranged from 30 to 68 (50.93 ± 9.44) years, classified according to the line of treatment into three groups, all received four sessions of ESWT 1 week apart.Group I: 15 patients received focused shock waves (F-SW) 1500 shocks.Group II: 15 patients received radial shock waves (R-SW) 2000 shocks.Group III: 15 patients received combined focused and radial shock waves (C-SW). All patients were evaluated by musculoskeletal ultrasound (MSK US) before treatment, at 1 week and at 3 months after the last session.Results: In the three studied groups, there was a significant improvement in shoulder pain, active range of motion (ROM), and shoulder function by shoulder disability questionnaire (SDQ) at 1 week after the end of treatment and after 3 months follow up. Moreover, there was a significant sonographic reduction in calcification size in the three groups. At the end of the study, the best improvement as regards a decrease of calcification size was obtained in group III when compared with group I and group II.Conclusion: These results demonstrated clinical, functional, and sonographic improvement in all groups. The best therapy in calcific shoulder tendinopathy appears to be combined focused and radial ESWT compared to interventions alone. Level 1 Evidence Randomized control study.


Subject(s)
Extracorporeal Shockwave Therapy , High-Energy Shock Waves , Tendinopathy , Adult , Aged , Extracorporeal Shockwave Therapy/methods , High-Energy Shock Waves/therapeutic use , Humans , Middle Aged , Range of Motion, Articular , Shoulder , Tendinopathy/diagnostic imaging , Tendinopathy/therapy , Treatment Outcome
3.
Clin Rheumatol ; 40(2): 557-564, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32623650

ABSTRACT

OBJECTIVES: This study was conducted to assess the safety and efficacy of intra-articular injection of etanercept and compare it with corticosteroid injection in rheumatoid arthritis (RA) patients. METHODS: Fifty patients with RA who suffered from activity in one joint were randomized into two groups, received an intra-articular injection of either etanercept or corticosteroid guided by musculoskeletal ultrasound. All patients were assessed for disease activity by disease activity score (DAS28), functional assessment using the Modified Health Assessment Questionnaire (MHAQ), and laboratory investigations (erythrocyte sedimentation rate and C-reactive protein). Joints affected were evaluated for pain by visual analog scale (VAS), tenderness, and swelling scores and by ultrasound for estimation of synovial hypertrophy, synovial effusion, and power Doppler. Follow-up of the patients was done at weeks 1, 4, and 12 after injection by clinical assessment and ultrasound. RESULTS: There was a significant improvement of joint pain assessed by VAS, tenderness, and swelling scores in the etanercept group at week 1 and week 4 follow-up periods but there were insignificant changes at week 12. There was a significant decrease in synovial effusion at week 1 and week 4 and in power Doppler at week 1 but no significant change was noticed in synovial hypertrophy during the follow-up periods. In comparison of the two groups, etanercept has shown better results on joint scores at week 1; however, glucocorticoid had more sustained effects. No major or life-threatening side effects were noticed following intra-articular injection of etanercept. CONCLUSION: Intra-articular injection of etanercept is a safe and promising option; with comparable results to intra-articular injection of corticosteroid; however, its rapid absorption from the synovium may necessitate frequent injections. Key Points • Persistent inflammatory mono-arthritis is a common clinical problem that is often difficult to treat; it is a debilitating and destructive condition. • Intra-articular injection of TNF inhibitors is an encouraging treatment modality in managing refractory mono-arthritis in rheumatoid arthritis.


Subject(s)
Arthritis, Rheumatoid , Glucocorticoids , Arthritis, Rheumatoid/drug therapy , Etanercept/therapeutic use , Glucocorticoids/therapeutic use , Humans , Injections, Intra-Articular , Synovial Membrane , Treatment Outcome
4.
Clin Rheumatol ; 39(5): 1627-1632, 2020 May.
Article in English | MEDLINE | ID: mdl-31907692

ABSTRACT

AIM OF THE WORK: To determine the role of Interleukin-34 (IL-34) in the pathogenesis of juvenile systemic lupus erythematosus (J-SLE), by exploring the relationship between IL-34 concentration and the disease activity SUBJECTS AND METHODS: This study was carried out on 48 children with SLE, and 30 healthy control subjects. SLE disease activity was measured by systemic lupus erythematosus disease activity index (SLEDAI). Serum IL-34 was measured by enzyme-linked immunosorbent assay (ELISA). The collected data were statistically analyzed using SPSS program version 16.0. RESULTS: There was a significant elevation in IL-34 concentration in J-SLE patients (52.25 ± 19.94 pg/ml) compared with control group (11.20 ± 6.40 pg/ml) (p < 0.001). The highest level was detected in patients with high SLEDAI score and with lupus nephritis (p = 0.005, 0.003, respectively). There was a statistically significant positive correlation between IL-34 levels and SLEDAI, ESR, CRP, and anti-ds DNA antibodies, but negative correlation with complement (C3, C4), and hemoglobin levels in J-SLE patients. CONCLUSION: IL-34 could be a probable marker for J-SLE disease activity which is more aggressive than adult-SLE, and IL-34 blockage may suppress the expression of proinflammatory cytokines in patients' blood.Key Points•Juvenile SLE is more aggressive and of worse prognosis than adult-SLE.• Significantly elevated concentration of IL-34 in juvenile SLE patients when compared with controls.• Elevated concentrations of IL-34 in patients are correlated with SLEDAI, ESR, CRP, ds-DNA antibodies, hemoglobin, and complement levels.• IL-34 may play a role in SLE pathogenesis and disease activity.


Subject(s)
Interleukins/blood , Lupus Erythematosus, Systemic/blood , Adolescent , Biomarkers/blood , Case-Control Studies , Child , Complement C3/immunology , Complement C4/immunology , Cross-Sectional Studies , Female , Humans , Linear Models , Lupus Erythematosus, Systemic/immunology , Male , Severity of Illness Index
5.
J Back Musculoskelet Rehabil ; 32(1): 55-62, 2019.
Article in English | MEDLINE | ID: mdl-30149440

ABSTRACT

OBJECTIVE: This study compared the effectiveness of regenerative injection therapy (RIT), i.e. prolotherapy, and repetitive transcranial magnetic stimulation (rTMS) in the treatment of fibromyalgia syndrome. PATIENTS AND METHODS: This study included 120 female, age-matched fibromyalgia patients. All patients underwent a clinical examination, pain assessment by VAS, assessment of tender points, psychiatric and functional assessment using the Beck Depression Inventory (BDI), Fibromyalgia Impact Questionnaire Revised (RFIQ), and measurement of cortical auditory evoked potentials CAEPs elicited at 1000 Hz. Patients were divided into two equal groups; Group 1 received prolotherapy three times, two weeks apart, and Group 2 received rTMS sessions every other day for one month. Assessment was performed before treatment, immediately after treatment, and one month later. RESULTS: A significant improvement of pain measured by the mean score of VAS was remarked in Group 1 compared to Group 2 immediately after treatment and one month later. There was statistically significant difference of mean scores for the number of tender points in Group 1 compared to Group 2 after treatment and one month later. The patients improved functionally, with a statistically significant difference in mean score of RFIQ, in Group 1 compared to Group 2 one month after treatment. However, there was a significant difference in mean score of BDI in Group 2 compared to Group 1 after treatment and one month later. Further, CAEPs showed better improvement, with a significant difference in Group 2, one month after treatment. CONCLUSION: RIT had the advantage in clinical and functional improvement in fibromyalgia patients, while rTMS had better results regarding depression and the cortical component of AEPs. These results might draw attention to the evaluability of a combination of both techniques for a better therapeutic response.


Subject(s)
Fibromyalgia/therapy , Prolotherapy/statistics & numerical data , Transcranial Magnetic Stimulation/statistics & numerical data , Depression/therapy , Female , Fibromyalgia/psychology , Humans , Pain/etiology , Pain Management/methods , Pain Measurement , Treatment Outcome
6.
Clin Exp Rheumatol ; 36(6 Suppl 115): 45-52, 2018.
Article in English | MEDLINE | ID: mdl-29745880

ABSTRACT

OBJECTIVES: To determine the types and to assess the role of auditory evoked potentials and otoacoustic emissions in early detection of hearing abnormalities in Behçet's disease (BD) patients. Their correlations with disease activity were also considered. METHODS: Thirty patients with BD and thirty apparently sex- and age-matched healthy volunteers were included in this study. Auditory evaluation included pure tone audiometry (PTA), otoacoustic emissions (TEOAEs, DPOAE), auditory brainstem response test (ABR) and cortical auditory evoked potentials (tone and speech CAEPs) for all patients and control. RESULTS: The highest abnormality of CAEP latencies elicited by (500Hz and 1000 Hz) as well as speech stimuli (da and ga) among our BD patients was delayed P1 and N1 waves at 80 dB with greater bilateral affection, as well as significant differences between patients and controls. All our BD patients had a smaller amplitude of distortion product OAE (DPOAE) and S/N ratio at 1, 2, 4, 6 kHZ compared with controls and the differences were highly statistically significant (p=0.0001). CONCLUSIONS: Being one of the autoimmune inner ear diseases (AIED), BD has a definite hearing impairment, even in the presence of normal hearing sensitivity, as evidenced by PTA. BD patients had a sub-clinical cochlear pathology which was not affected by disease activity or different organ affection. DPOAE (S/N ratio) proved to be a sensitive test in detecting minimal changes in cochlear pathology and the latencies of CAEPs (tone and speech) measures were considered as sensitive indicators (100%) of early detection of hearing impairment in BD patients.


Subject(s)
Auditory Pathways/physiopathology , Behcet Syndrome/complications , Evoked Potentials, Auditory, Brain Stem , Hearing Disorders/diagnosis , Hearing Tests/methods , Otoacoustic Emissions, Spontaneous , Acoustic Stimulation , Adult , Audiometry, Pure-Tone , Audiometry, Speech , Auditory Threshold , Behcet Syndrome/diagnosis , Case-Control Studies , Early Diagnosis , Electroencephalography , Female , Hearing Disorders/etiology , Hearing Disorders/physiopathology , Humans , Male , Predictive Value of Tests , Reaction Time , Severity of Illness Index , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...